S_y The expron of tumour nerosis factor a (TNF-a) and its two distiwt receptors, TNF-R p55 and TNF-R p75, was asessed by immunocytochemistry in 28 pnmary brast cancer and three reducton mammopla spemens ('normal' breast tissue (Schuger et al., 1989) . Alternatively, the protumour effects of this cytokine include promotion of angiogenesis at low doses (Fajardo et al., 1992) and stimulation of the metastatic potential of ovarian carcinoma cells in rodent tumour models (Malik et al., 1990) . However, the multfaceted role(s) of this cytokine within solid tumours is largely unknown. Similarly, the cellular targets of TNF-1 in these tumours have yet to be fullly identified.
Lymphocytes and macrophages represent a potential source of the cytokine TNF-x within the tumour microenvironment. Indeed, lymphocytes (CD4+, CD8+ cells) isolated from breast cancer biopsies secrete TNF-x in vitro (Rubbert et at., 1991) , and the in situ production of TNF-z mRNA by cells in malignant breast tumours has recently been demonstrated (Miles et al., 1992) .
TNF-a may be directly cytotoxic or cytostatic for tumour cells or help both to recruit infiltrating cells to the tumour site and to stimulate their tumoricidal activity (reviewed by Balkwill, 1991) . It may also induce haemorrhagic necrosis within tumours by its activity on endothelial cells (Schuger et al., 1989) . Alternatively, the protumour effects of this cytokine include promotion of angiogenesis at low doses (Fajardo et al., 1992) and stimulation of the metastatic potential of ovarian carcinoma cells in rodent tumour models (Malik et al., 1990) . However, the multfaceted role(s) of this cytokine within solid tumours is largely unknown. Similarly, the cellular targets of TNF-1 in these tumours have yet to be fullly identified.
In this preliminary study, the cellular distribution of TNFa and its two distinct TNF receptors (TNF-R p55 and p75) was investigated by immunohistochemistry on frozen sections of humnn breast cancer biopsies. To assess the possible contribution of TNF-a to the activity of breast cancer cells in situ, the expression of the above cytokine parameters was correlated with: (i) proliferative activity, (ii) neovascularisation, (iii) degree of metastasis (lymph node status), (iv) tumour grade and (v) degree of lymphoid infiltration. 
Results
The results are summarised in Table H 
Expression of TNF-receptor p55
Stromal cells in all 28 tumours showed immunoreactivity with monoclonal antibody htr-9. The proportion of immunoreactive cells in individual breast cancers varied from 10% to 50% of the total stromal cell population. The signal was often detected in elongate, fibroblast-like cells ( Figure  lb) . A subpopulation of mononuclear cells (10%) within nests of infiltrating leucocytes were also positive for the TNF-R p55 (Figure lc) . In the majority of cases (82%) the microvasculature also expressed this receptor (Figure ld) . However, not all capillary endothelial cells identified by CD31 expression were positive for TNF-R p55. No association between endothehal immunoreactivity and degree of angiogenesis, as assessed by the number of blood vessels present, was observed. Similarly, no association between endothelial staining and lymph node metastasis or the extent of intratumour necrosis was detected. However, a significant correlation (X = 15.48, P = 0.02) between the expression of TNF-R p55 by blood vessels and the amount of leucocyte infiltration (LCA-positive cells) present in the tumour was noted. Normal breast epithelial structures adjacent to tumour was present in eight cases. In six of these, ductal epithelial cells showed cytoplasmic immunoreactivity (data not shown). In the other two cases the same structures were negative. Sporadic, elongated fibroblast-like cells from reduction mammoplasty also showed immunoreactivity with htr-9 (not shown).
In 75% of the tumours (one mixed, one medullary and 19 ductal cancers) neoplastic cells of both in situ and invasive components expressed TNF-R p55 (Figure le) Although the number of tissues used in this study was relatively small, our preliminary observations suggest that expression of TNF and its receptor is up-regulated in the majority of breast carcinomas when compared with 'normal' breast tissue. However, it should be noted that the latter group comprised non-malignant breast tissue adjacent to the tumours and reduction mammoplasty samples, neither of which may accurately represent normal breast tissue.
That TNF-x immunoreactivity was confined to sporadic, macrophage-like cells in the stroma of breast tumours accords well with previous reports demonstrating a similar pattern of expression of TNF-x mRNA (Miles et al., 1992 (Wright et al., 1992 Activated, but not unstimulated, T cells express TNF receptors both in vitro and in vivo (Ware et al., 1991) . The lack of expression of TNF-x and its receptors by the majority of tumour-infiltrating mononuclear cells may reflect the relative absence of activated leucocytes in breast carcinomas. Indeed, other leucocyte activation markers (IL-2 receptor, IgE receptor, transferrin receptor) were also expressed by only a few tumour-infiltrating leucocytes in these tumours (L. Pusztai, C.E. Lewis & J.O'D. McGee, unpublished observations). However, it should be noted that such immunophenotypic activation markers are characterised in in vitro assays and may not reflect the functional status of tissue leucocytes.
It is difficult to assess the possible biological significance, if any, of the aforementioned expression and cellular distribution of TNF-x and its receptors in breast tumours, especially since it could not be correlated with the proliferative and metastatic potential of the neoplastic cells, the angiogenic activity and degree of leucocyte infiltration of tumours, and routine prognostic indicators such as tumour size and grade. However, the small number of cases involved in this preliminary study means that a weak correlation between the presence of TNF-x or TNF receptors and the biological behaviour of the tumours may not have been detectable. It is also possible that TNF-x and its receptors play a more important role in the progression of early (preclinical) breast tumours rather than those used in this study, which were clinically manifest and, therefore, biologically quite advanced.
